LadRx Corporation Email Format
Biotechnology ResearchUnited States11-50 Employees
LadRx Corporation is a United States-based biotechnology company focused on discovering and developing new therapeutics to treat cancer. Its notable programs include aldoxorubicin, an improved version of doxorubicin that has been licensed to ImmunityBio, and arimoclomol, which was sold to Orphazyme (now Zevra Therapeutics) with milestone and royalty arrangements. The company operates within the biotechnology research sector and collaborates with other developers to advance its assets for cancer patients. In 2023, LadRx completed an asset transfer to XOMA Corporation, with XOMA Royalty acquiring related rights.